Compare BioNTech SE - ADR (BNTX) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Hasbro, Inc. — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Hasbro, Inc. trades at $78.85 (market cap $11.10B). The key difference: BioNTech SE - ADR is far larger — about 2.1× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.57% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | HAS | |
|---|---|---|
Market Cap | $22.86B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $105.88 |
52-Week Low | $83.89 | $70.95 |
Enterprise Value | $6.53B | $13.37B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Hasbro (HAS) trades at $79.53, showing modest daily gains but facing bearish technical signals. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B, with profitability metrics showing strain. Recent earnings beats provide some optimism, while analyst consensus remains positive with a $104 price target representing 31% upside potential from current levels.
Investment outlook balances strong analyst support against fundamental challenges. The stock offers significant upside if management can improve profitability, but faces headwinds from negative margins and high debt levels. Key catalysts include Q2 2026 earnings on July 21 and execution of the company's 'aging up' strategy targeting adult consumers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
